Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LXRX 1.91.
LXRX daily
PLX 1.61 Setting up for a pinch.
SCYX 2.96. I like the curves.
https://stockcharts.com/c-sc/sc?s=SCYX&p=D&yr=0&mn=3&dy=10&i=p98365817596&a=785057520&r=1595002948255[/url][tag]EVAX
I was just looking at a couple this morning that were on my all time list a few years ago, DYNT and BBIG. Both look to be going BK in the near future. Or the same 'ol same 'ol of continuous dilution, RS and repeat.
KULR may have a chance if they can learn to manage correctly.
IMO of course.
I've just been keeping it simple. A few swings is about it. This may not even stay on my list.
Nice pop for sure!
rediculous float. https://finviz.com/quote.ashx?t=ENSC&p=d
Anything good happens here and what's left of the shorts will be toast. Offering was in the 3.80's.
Presentation coming up in Las Vegas.
Roll the dice baby!!
DFFN looking to merge too, August 15th. Keeping an eye on it. Merging with Epi Pharma (private company). DFFN float is just over 2M right now.
https://www.sec.gov/Archives/edgar/data/1053691/000143774923019881/dffn20230712c_424b3.htm
RS, again? And of course followed with dilution...
We are offering on a reasonable best efforts basis up to 4,651,163 units, each unit consisting of one share of common stock and one common warrant to purchase one share of common stock, at an assumed offering price of $2.15 per unit, which is equal to the closing price of our common stock on the Nasdaq Capital Market on July 7, 2023. The common warrants included in the units will have an exercise price of $ per share, will be exercisable immediately and will expire five (5) years from the date of issuance. We are also offering the shares of our common stock that are issuable from time to time upon the exercise of the common warrants included in the units.
Rinse and repeat. Float is small enough to give massive volatility. Might pick up a few if it dips under $2 again. "If" Thinking it's almost a certainty. Guese I haven't looked at this in quite a while.
edit: Looking back now I remember why I've been avoiding this one.
https://finance.yahoo.com/news/adamis-pharmaceuticals-seeks-strategic-options-102744674.html
GORO high .6656
25% is good enough for me. It may have a bit more momentum for a move to the .70's. I'll try and keep an eye on it.
This could get interesting very soon. https://ih.advfn.com/stock-market/NASDAQ/hillstream-biopharma-HILS/stock-news/91550551/form-8-k-current-report
10.88 price target. https://fintel.io/sfo/us/evax?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget
I was looking for the $, we'll see which hits first!
EVAX[/url][tag]EVAX daily
Looks like his wife needed new shoes.
lanation of Responses:(1) The shares of common stock are held by the Reporting Person's spouse, Marianne Knight. Mr. Knowles does not have direct voting or dispositive control over the shares owned by Ms. Knight. The Amount of securities beneficially owned following the reported transactions do not include Mr. Knowles' direct ownership over 15,600,000 shares, which amount remains unchanged since Mr. Knowles' initial acquisition of the Company's common stock.(2) On June 28, 2023, Marianne Knight, Mr. Knowles' spouse, sold 38,244 shares of common stock of the Company at a price of $0.643546 per share.(3) On June 29, 2023, Marianne Knight, Mr. Knowles' spouse, sold 61,756 shares of common stock of the Company at a price of $0.622223 per share.
$EVAX (1.23) bollinger coming together nicely. This set up may dip it to around 1.10. See how it sets up on low volume.
[url]$EVAX (1.23) bollinger coming together nicely. This set up may dip it to around 1.10. See how it sets up on low volume.
https://stockcharts.com/c-sc/sc?s=EVAX&p=D&yr=0&mn=3&dy=10&i=p98365817596&a=785057520&r=1595002948255[/url][tag]EVAX daily[/tag]
I like this. And I was with family so missed the dip....
"And just giving it a second to think about it, the increase of 40 million authorised shares is just prudent and responsible given the low 33 million count remaining they could be at. Nor does it mean that they will suddenly dump all the shares. "
That's exactly shorty trying to shake out the weak hands. This happens all the time and is an easy target for shorts to take advantage of. Exasperated by low volumes it's easy to bring on the volatility.
Anyway, I see this in a positive way and will be watching to add.
NEWS from June 16th: NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
NovAccess Global Inc.
NovAccess Global Inc.
June 16, 2023
In this article:
XSNX
+4.76%
Watchlist
Watchlist
CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a partnership with Thailand-based CKN Ventures Limited, a multifaceted clinical and commercial healthcare platform, to expand clinical data set access in Southeast Asia to enhance and accelerate personalized therapeutics and treatment protocols. This partnership supports NovAccess Global's new Precision Medicine Division, launched earlier this month, to develop the most comprehensive collection of personalized therapeutics and treatment protocols using artificial intelligence (AI), Big Data and Predictive technologies.
Using advances in AI, image recognition and predictive data science, NovAccess Global and CKN Ventures will collaborate to expand access to relevant data sources in Asia that will improve the quality and impact of licensed databases to identify patient data (phenotypic, clinical, and genomic) for analysis relating to therapeutic drug development and therapeutic treatment purposes. Therapeutic and treatment protocol data will be marketed to external pharmaceutical and biotechnology companies, private payers, national/international health agencies and healthcare providers and insurers.
According to Market.us, the global precision medicine market size was $83.4 billion in 2022 and is projected to reach $254 billion by 2032, exhibiting a compounded annual growth rate of 12.1% in the forecast period (2023-2032). Asia is the fastest growing market in the world for the delivery of innovative care in oncology and immune oncology therapeutics, all of which depend upon management of robust, high-quality data sets to discover new treatment pathways.
Commenting on the latest development to expand the Company's new Precision Medicine Division, NovAccess Global's Chief Executive Officer Dr. Dwain K. Irvin said, "We are very excited to publicly announce our partnership with CKN Venture Limited's world-class team of physicians and data scientists to expand access to critical data streams in Asia to better serve patients facing cancer and other diseases, globally. As part of the initial contributions from CKN, we expect to accelerate and expand our collection of patient data primarily through their glioblastoma database from multiple southeast Asian countries. Furthermore, CKN offers a wide variety of other support services and collaborative opportunities through their basic science and clinical laboratories. Together, we will also have opportunities to bring our technology to Asia and collaborate and develop novel therapeutics and diagnostics."
"Joining forces with NovAccess Global will not just expand the quality of data sources available to both companies and improve our combined geographical reach, but will allow for CKN Ventures to drive a generation of new and enhanced targeted data sets by providing molecular and genomic sequencing capabilities from its Bangkok-based laboratory and wholly owned subsidiary, Phoenix Molecular," said CKN Ventures Director Supornchai Kongpatanakul, MD. "We view CKN's strengths in bioinformatics, molecular diagnostics, and the development of digital health systems to be complimentary to NovAccess Global's assets in therapeutics and precision medicine. Together, the two companies will leverage their combined talents to identify new breakthroughs in cancer and chronic disease management through this unique collaboration."
NovAccess Global intends to also use AI within these data sets to identify the most optimal antigens to use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient.
It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.
In partnering with NovAccess Global, CKN Ventures is positioned to support trials of the Company's therapeutic candidate in glioblastoma patients in both North America and Asia. Dr. Supornchai added, "Our proven capabilities in genomics and bioinformatic analysis will help to support NovAccess Global's trial design and assist in measuring patient response to this groundbreaking therapy while providing research and pharmaceutical entities with data on various variables such as biomarkers and clinical outcomes."
About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
Follow us on social media and stay up to date on all of our developments:
https://www.youtube.com/@novaccess
https://www.facebook.com/novaccessglobal
https://www.linkedin.com/company/64892686
https://twitter.com/novaccessglobal
ABOUT CKN VENTURES, LTD.
CKN Ventures is a group of technology companies based in Thailand with offices and facilities in Thailand and Singapore and serving both ASEAN and international regions. We focus on advanced diagnostics and technology-based precision medicine that enables physicians to deliver personalized care to patients with Cancer and other chronic or infectious diseases. Founded in 2019 we apply advanced technologies and artificial intelligence (AI) to process diverse peer reviewed data (genome, medical test results, medications, lifestyle etc.) on patients and utilize the latest medical research to generate personalized prescriptions/care plans. The personalized care plans go beyond the current standard-of-care and utilize targeted combinations of existing treatments to deliver better patient outcomes for target diseases as well as lowering healthcare costs. Physicians use our care plans as a guide to treat patients uniquely based on analysis including a battery of existing clinical tests, their genome, and their disease status, and do so in a fast and economical package.
Our initial products address the spectrum of cancers with a personalized combination therapy which deliver better patient outcomes than the standard-of-care. Physicians are provided with a detailed and comprehensive report which outlines individual genomic details and suggests the most appropriate therapies to administer based on individual genetic analysis. The AI based software which creates Physician Reports is regularly updated as new therapeutic techniques and drugs are constantly being developed, published, and approved.
CKN also owns and manages registered diagnostic labs outfitted with State-of-the-Art equipment and highly trained personnel. We have a catalogue of esoteric molecular and immunological diagnostic assays and also create and develop our own "LDT's" (Lab Developed Tests), including reagents, testing formats, and equipment/automation.
The Company is also developing a distribution network to sell the diagnostic kits and processes we acquire and develop to hospitals and clinical lab networks throughout ASEAN countries. We are creating a combination of in-house sales force and large regional corporate partnerships for distribution of registered kits and select genomic sequencing services for cancers. CKN also is highly experienced in Regulatory Approvals and running Clinical Trials.
Forward-Looking Statement for for NovAccess Global
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
Investor Relations Contact for NovAccess Global:
Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com
Contact for CKN Ventures:
Supornchai Kongpatanakul, M.D.
+66 81 836 7987
supornchai@cknventures.com
SOURCE: NovAccess Global Inc.
View source version on accesswire.com:
https://www.accesswire.com/761806/NovAccess-Global-Partners-with-CKN-Ventures-to-Expand-its-New-AI-driven-Precision-Medicine-Division
Anything can happen.
All it takes is the right person to hold their hand and for them to listen.
$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...
Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
Hmmm. Just a hunch something is coming up soon. Gotta be right? Time passages.
They wasted no time issuing their milestone warrants. I'm thinking shorts took advantage as well. PM dip into the 1.30's, which I was able to take a nice partial (that remains to be seen if it turns out to be nice) right at 1.40.
Short term dip because of the warrants, I see this bouncing pretty good sooner or later.
Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
EDIT" Gap filled, I'll take smoe here. 1.50's.
Potential support here, 1.60's. doesn't need to fill th gap in 1 day imo.
Shorty sure had his fun too.
EVAX pushing on news 2.13. +43%
Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
5:00 pm ET June 3, 2023 (Globe Newswire) Print
GlobeNewswireJune 03, 2023
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability
Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients
High-quality neoantigens, predicted by AI technology, were associated with longer progression-free survival
Strong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients
Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome
COPENHAGEN, Denmark, June 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois.
The Phase 1 trial successfully met primary endpoints for safety and tolerability of EVX-01 in metastatic melanoma patients and demonstrated positive clinical responses in 8 out of 12 (67%) treated patients. In addition, Evaxion's proprietary AI technology PIONEER(TM) was able to identify high-quality cancer vaccine targets, so-called neoantigens, associated with longer progression-free survival.
"We are excited that our AI technology could effectively identify vaccine neoantigens associated with better clinical responses and longer progression-free survival. And the data suggest a treatment effect, with response rates nearly double of those observed in historical data for checkpoint inhibitors. Our findings in this study position us well to prospectively identify patients who will benefit from personalized cancer immunotherapy for our upcoming trials, potentially making the benefit for patients even greater," said Per Norlen, Chief Executive Officer of Evaxion.
The study demonstrated the ability of the PIONEER(TM) platform to identify vaccine targets that are associated with improved patient outcomes. Stratification based on PIONEER(TM) scores outperformed tumor mutational burden as a predictive biomarker, with patients having high-quality neoantigens showing better treatment responses and longer progression-free survival.
The evaluation of treatment-related immune responses revealed strong neoantigen T-cell responses in all 12 patients, mediated by activated CD4+ T cells in all cases and CD8+ T cells in 7 out of 12 patients. Further, immune response magnitude correlated with the vaccination dose.
"The positive association between clinical outcome and prevalence of immunogenic cancer neoantigens validates the PIONEER(TM) platform for its use for personalized cancer vaccines and emphasizes the importance of a robust AI system for designing neoantigen vaccines. Moreover, the dose-dependent increase in responses has been instrumental for Phase 2 dose selection in the ongoing clinical trial. We have great expectations on the upcoming interim Phase 2 results that are planned to be presented later this year," Per Norlen continues.
About the Phase 1 Study with EVX-01
The open-label, single-arm, single-center Phase 1 study, titled "Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)" (ClinicalTrials.gov Identifier: NCT03715985), was conducted in collaboration with DTU, SSI, the center for genomic medicine at Rigshospitalet and CCIT-DK and aimed to assess the safety and efficacy of EVX-01 vaccine in combination with anti-PD1 (pembrolizumab or Nivolumab) in patients with metastatic melanoma. The design consisted of multiple 15-27mer peptides comprising one or more patient-specific neoantigens formulated with the novel liposomal adjuvant CAF(R)09b to potentiate immune responses. The primary objective was to determine the safety and tolerability of the combination of EVX-01 and a checkpoint inhibitor. Additional objectives were to evaluate manufacturing feasibility, immune responses, and clinical efficacy.
About Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage biotech company focused on harnessing the power of artificial intelligence to decode the human immune system and develop immunotherapies for cancer, bacterial diseases, and viral infections. Through its proprietary AI platform, PIONEER(TM), Evaxion aims to revolutionize cancer treatment by identifying unique and immunogenic neoantigens and designing individualized therapies. The Company is committed to transforming the lives of cancer patients with unmet clinical needs by providing innovative and targeted treatment options. For more information about Evaxion Biotech and its groundbreaking personalized cancer immunotherapies, please visit www.evaxion-biotech.com.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available atâ?¯www.sec.gov.â?¯We do not assume any obligation to update any forward-looking statements except as required by law.
Of course that would be great to see. This is one I continue to accumulate on.
Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
2.75 support. See how it holds, or not. Interesting sell off.
Over the $ and regain compliance BEFORE September.
Who's crystal ball works better?
PLX 2.20 Setting up again.
https://stockcharts.com/h-sc/ui?s=PLX&p=W&b=5&g=0&id=p86431144783
Protalix BioTherapeutics set to join Russell 3000
https://finance.yahoo.com/news/protalix-biotherapeutics-set-join-russell-105000952.html
Excellent news. Protalix BioTherapeutics set to join Russell 3000® Index
https://finance.yahoo.com/news/protalix-biotherapeutics-set-join-russell-105000952.html
Take a look at the weekly as well, a LOT of running room.
https://finviz.com/quote.ashx?t=PLX&p=w
Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
KULR Wins Additional Order from U.S. Military
https://ih.advfn.com/stock-market/AMEX/kulr-technology-KULR/stock-news/91125861/kulr-wins-additional-order-from-u-s-military
$WATT .33 Now maybe we'll see if this puppy has any life left. A pulse even.
WATT daily
Filled some 2.33's. Maybe a little early. I like anywhere here to the $2 mark. Lower bollinger 2.08.
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
Thinking the gap continues to go unfilled.
https://finance.yahoo.com/news/scynexis-reports-closing-exclusive-license-120000142.html
With this market volatility one just needs to be in the right place at the right time. And imo, KULR isn't one of those places. My chart is what I was looking at (that's where my target of 1.18 came from) but i give this about nil chance anytime soon.
Next few weeks we just may get a glimps of what this summer will lok like.
Upward resistance area. 1.20's. IF they can get some momentum going...... EVER.
If I se what I think I see, there's a reason shorts are leaving this puppy alone.
Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
Only my mouth is watering watching for the gap to fill. short term double bottom @ 2.80. I'm thinking we see lower (very short term). Not sure how long the dip will last.
bullish longer term.
Golden cross came thru end of April.